Constellation Pharmaceuticals announces a Phase 2 study for MF Patients
February 22, 2018
Constellation Pharmaceuticals announced a Phase 2 study of CPI-0610 alone or in combination with ruxolitinib in patients with myelofibrosis. This study is for MF patients who are currently taking ruxolitinib but have a sub-optimal response or for patients who are resistant, intolerant or have lost response to a JAK inhibitor. Click here for more information about the study or click here for more information about CPI-0610 and Constellation Pharmaceuticals.